Editorial: Advances in Understanding the Mechanisms of Pulmonary Hypertension
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Sitbon O, Channick R, Chin K, Frey A, Gaine S, Galie N
. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522-33.
DOI: 10.1056/NEJMoa1503184.
View
2.
Joshi S, Liu J, Bloom T, Atabay E, Kuo T, Lee M
. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. Sci Rep. 2022; 12(1):7803.
PMC: 9098455.
DOI: 10.1038/s41598-022-11435-x.
View
3.
Ruopp N, Cockrill B
. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022; 327(14):1379-1391.
DOI: 10.1001/jama.2022.4402.
View
4.
Soon E, Holmes A, Treacy C, Doughty N, Southgate L, Machado R
. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010; 122(9):920-7.
DOI: 10.1161/CIRCULATIONAHA.109.933762.
View
5.
Cheadle C, Berger A, Mathai S, Grigoryev D, Watkins T, Sugawara Y
. Erythroid-specific transcriptional changes in PBMCs from pulmonary hypertension patients. PLoS One. 2012; 7(4):e34951.
PMC: 3335832.
DOI: 10.1371/journal.pone.0034951.
View